SCHEMBL3018014

SCHEMBL3018014

O=S(=O)(c1ccc(Cl)cc1Cl)N1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.57
HSD11B1 P28845 2/20 0.45
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.41
LPAR1 Q92633 1/20 0.40
LPAR2 Q9HBW0 1/20 0.40
KDM4E B2RXH2 2/20 0.39
GAA P10253 2/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
THRB P10828 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021382 0.94 TRPV4 (0.48) TRPV4HSD11B1MEN1LMNAKMT2A
SCHEMBL3023185 0.92 TRPV4 (0.47) TRPV4MEN1LMNAKMT2AMAPK1
SCHEMBL3009094 0.91 TRPV4 (0.47) TRPV4HSD11B1MEN1LMNAKMT2A
SCHEMBL3015465 0.90 TRPV4 (0.45) TRPV4HSD11B1MEN1LMNAKMT2A
SCHEMBL3013342 0.90 TRPV4 (0.45) TRPV4HSD11B1ALDH1A1SMN1; SMN2LPAR1
SCHEMBL2999239 0.90 KMT2A (0.48) TRPV4HSD11B1MEN1LMNAKMT2A
SCHEMBL3017760 0.90 TRPV4 (0.45) TRPV4MEN1LMNAKMT2AMAPK1
SCHEMBL3012898 0.89 CHRM4 (0.47) TRPV4MEN1LMNAKMT2AMAPK1
SCHEMBL3008696 0.89 TRPV4 (0.47) TRPV4HSD11B1MEN1LMNAKMT2A
SCHEMBL3006210 0.89 TRPV4 (0.47) TRPV4HSD11B1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885HSD11B1 1034/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.